McKesson stock gains as fiscal 2027 earnings outlook rises
Published on 11/11/2026 at 16:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMcKesson raises fiscal outlook
- Second-quarter revenue increased 8% year over year, while adjusted diluted EPS rose 18%.
- Management lifted fiscal 2027 adjusted EPS guidance and expects continued growth across key operating segments.
- Investors will next focus on McKesson's scheduled appearance at the Jefferies Global Healthcare Conference.
McKesson reported stronger fiscal second-quarter results on Wednesday, November 4, 2026, and raised its full-year adjusted earnings outlook. In its earnings release, the company said revenue for the quarter ended September 30 increased 8% year over year to 111.0 billion US dollars. McKesson stock traded at 966.00 euros on Lang & Schwarz at 16:09 CET on Wednesday, November 11, 2026, 1.10% above the 955.50-euro quote in the November 9 report.
Quarterly growth supports guidance
Adjusted diluted EPS rose 18% to 11.68 US dollars from 9.86 US dollars a year earlier. GAAP diluted EPS increased to 10.44 US dollars from 8.92 US dollars. McKesson attributed the adjusted earnings growth to operating gains in North American Pharmaceutical, Oncology & Multispecialty, and Prescription Technology Solutions, together with a lower share count.
North American Pharmaceutical revenue increased 6% to 91.4 billion US dollars, while adjusted segment operating profit rose 22% to 1.0 billion US dollars. Oncology & Multispecialty revenue climbed 24% to 15.0 billion US dollars, with adjusted operating profit up 8% to 427 million US dollars. Medical-Surgical Solutions grew revenue 5%, but its adjusted operating profit fell 10% because of product mix in the ambulatory care channel.
Higher outlook raises execution bar
McKesson lifted fiscal 2027 adjusted diluted EPS guidance to 45.60 to 46.40 US dollars from 44.20 to 45.00 US dollars. The new range implies 17% to 19% growth from the prior fiscal year. Management also expects fiscal-year revenue growth of 6% to 10% and adjusted operating-profit growth of 12% to 16%.
The company completed its Precision Medicine Group acquisition on November 2 and extended its pharmaceutical distribution partnership with CVS Health through June 2032. The transactions broaden McKesson's oncology, multispecialty and biopharma-services exposure, while the raised outlook puts greater focus on second-half execution.
McKesson Corporation
- ISIN: US58155Q1031
- Ticker: MCK
- Home exchange: New York Stock Exchange
- Lang & Schwarz quote: 966.00 euros on November 11, 2026 at 16:09 CET
- Fiscal quarter: Second quarter ended September 30, 2026
Investors can follow the broader US equity market through current S&P 500 market coverage.
McKesson is scheduled to present at the Jefferies Global Healthcare Conference on November 17, 2026. More news and analyses on McKesson stock are available in the company coverage.
